Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
|
|
- Dustin Erick Potter
- 5 years ago
- Views:
Transcription
1 Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier (UNII): Ixazomib citrate: MLN9708; proteasome inhibitor MLN9708, UNII: 46CWK97Z3K Lenalidomide: CC-5013, CC5013, CDC 501, IMID-1, Revlimid, UNII: F0P408N6V4 Dexamethasone: Decadron, Dex, UNII: 7S5I7G3JQL Common Names or Abbreviations for Regimen: IRD, RID Mechanism(s) of Action: Ixazomib is a reversible proteasome inhibitor. It preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma (MM) cell lines in vitro. This agent demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model. U.S. FDA-Approved Indication(s): Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. 1 Approval was based on outcomes of the pivotal international, randomized, doubleblind, placebo-controlled clinical trial TOURMALINE-MM1, of 722 patients designed to evaluate the superiority of ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/ or refractory multiple myeloma. 2 It was announced earlier, February 10, 2015, that the TOURMALINE-MM1 trial achieved its primary endpoint of improving progression-free survival (PFS) at the first pre-specified interim analysis. In the trial, patients treated with investigational ixazomib plus lenalidomide and dexamethasone lived without their disease worsening for a significantly longer time compared to patients who received placebo plus lenalidomide/dexamethasone. 3 1
2 NCCN Recommended Use(s): IRD is recommended as primary therapy for transplant candidates; primary therapy for non-transplant candidates; and therapy for previously treated multiple myeloma. NCCN Preferred Regimen or Other: Both 4 Preferred Regimen: IRD is a preferred regimen as therapy for previously treated multiple myeloma. Note: This recommendation is consistent with U.S. FDA-approved indication. Other: IRD is not a preferred regimen, but is listed under other regimens as a primary therapy for transplant candidates and as a primary therapy for non-transplant candidates. Note: This recommendation is outside of the U.S. FDA-approved indication at this time. NCCN Category of Evidence 4 : IRD as a preferred regimen for previously treated multiple myeloma is a category 1 recommendation. IRD as listed under Other regimens as a primary therapy for transplant candidates and as primary therapy for non-transplant candidates is a category 2A recommendation. Dose Schedule: Newly diagnosed, untreated MM: Ixazomib 4 mg/day PO on days 1, 8, and 15 for up to twelve 28-day induction cycles; lenalidomide 25 mg/day PO on days 1 21 for up to twelve 28-day induction cycles; and dexamethasone 40 mg/day PO on days 1, 8, 15, 22, for up to twelve 28-day induction cycles. Note: Dose modifications of all three drugs were permitted for toxic effects. Patients were allowed to interrupt therapy so they could undergo stem cell collection after 3 cycles and discontinue for autologous stem cell transplant (ASCT) after 6 cycles. After primary induction therapy, maintenance with oral ixazomib was given on days 1, 8, and 15 every 28 days until progression at the last tolerated dose of induction therapy. 5,6 TOURMALINE MM-2 is the ongoing phase III part of this study. Relapsed/Refractory MM [TOURMALINE-MM1, Phase III study]: Ixazomib 4 mg/day PO on days 1, 8, and 15 on a 28-day cycle; lenalidomide 25 mg/day PO on days 1-21 on a 28-day cycle; dexamethasone 40 mg/day PO on days 1, 8, 15, and 22 on a 28-day cycle. Treatment was administered until disease progression. 2 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
3 Safety: There are no black box warnings for ixazomib as the drug is not yet FDA approved. Black box warnings for lenalidomide and dexamethasone exist however. Common side effects and warnings include: Black box warnings for lenalidomide include embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism. The most common side effects of lenalidomide in MM ( 20%, per Celgene package insert, Revlimid, 2015) 7 include fatigue, neutropenia, constipation, diarrhea, muscle cramps, anemia, pyrexia, peripheral edema, nausea, back pain, upper respiratory tract infection, cough, dyspnea, dizziness, thrombocytopenia, tremor, insomnia, decreased appetite, and rash. Additional warnings and precautions for lenalidomide in MM are rare, but should be considered, and include: Allergic reactions: Hypersensitivity, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis. If these occur, lenalidomide should be discontinued. Tumor lysis syndrome (TLS): Cases of TLS have been reported. Monitor for if disease burden high. Hepatotoxicity: Hepatic failure (including fatalities) has occurred. Liver function should be monitored. If hepatotoxicity is suspected, lenalidomide should be stopped. Second primary malignancies (SPMs): A higher incidences of SPMs were observed in controlled trials of patients with multiple myeloma receiving lenalidomide. Patients should not become pregnant when taking lenalidomide. Two reliable methods of contraception should be used while on therapy. IRD Fifty patients were enrolled in the phase II study of IRD as primary induction therapy in newly diagnosed, untreated multiple myeloma 5 ; 29 patients discontinued the study to proceed to transplant. All patients reported at least one drug-related event [65 patients (100%)]. In the total phase I/II study group, 49 (75%) patients had at least one adverse event (AE) of grade 3. Grade 3 or higher AEs related to any drug were reported in 41 (63%) patients, including skin and subcutaneous tissue disorders in 11 (17%) patients, neutropenia in 8 (12%) patients, and thrombocytopenia in 5 (8%) patients; drug-related peripheral neuropathy of 3 occurred in 4 (6%) patients. Five patients discontinued because of adverse events. Phase I/II safety profile of IRD (phase I, phase II and modified intention-to treat populations). 6 3 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
4 AEs led to dose reductions in 37 (57%) patients, including eight (53%) of 15 in the dose-escalation cohort and 29 (58%) of 50 in the phase II cohort. The most common AEs resulting in dose reductions included skin and subcutaneous tissue disorders (13 patients, 20%), fatigue (9 patients, 14%), diarrhea (5 patients, 8%), peripheral neuropathy not elsewhere classified (5 patients, 8%), insomnia (4 patients, 6%), and increased body weight (4 patients, 6%). AEs leading to discontinuation of study treatment were reported in five patients. The only grade 4 drug-related adverse events were thrombocytopenia in two (3%) patients (one each in phase I and phase II), and neutropenia in two (3%) patients (both in phase II), all during induction with ixazomib/lenalidomide/dexamethasone. Two patients in the phase II cohort died during the study, one due to respiratory syncytial viral pneumonia that was thought to be related to treatment, and one due to cardiorespiratory arrest that was not thought to be related to treatment. Only treatment-emergent peripheral neuropathy (PN) of any type was observed in 28 (43%) patients; four reported PN at baseline. o PN was grade 1 in most patients (17, 26% patients), with grade 2 reported in 7 (11%) patients o Grade 3 PN was reported in 4 (6%) patients; one painful grade 3 PN Of 39 separate PN events, 19 (49%) [17 grade 1, and 2 grade 2] had resolved at the time of last follow-up (median 1.4 months [IQR ]). Drug-related AEs. 6 4 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
5 5 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
6 Required Supportive Care/Prophylaxis: Patients on this regimen are at an increased risk for pneumonia, varicella zoster virus (VZV) or shingles reactivation, venous thromboembolic events (VTE), and PN. The following recommendations should be considered: Pneumococcal infections are common in patients with multiple myeloma. Pneumococcal vaccination should be completed at the time of diagnosis and repeated in 5 years to minimize preventable illness (link to CDC guidelines: Antiviral prophylaxis with acyclovir or valacyclovir to prevent herpes zoster infections is recommended for patients receiving proteasome inhibitors. Thromboprophylaxis with aspirin or low molecular weight heparin is advised in patients receiving immunomodulatory drug regimens due to the high incidence of venous thrombosis observed. Patients should be educated as to the signs and symptoms of PN and report the onset or worsening of PN symptoms immediately. Dose reduction or discontinuation of ixazomib may be warranted. Bisphosphonates (zoledronic acid or pamidronate) are intended to decrease the risk of skeletal related events and should be considered in all patients with MM receiving first-line therapy, regardless of presence of osteolytic bone lesions on conventional radiography. Dental health should be evaluated at baseline and an ongoing basis to assess for osteonecrosis of the jaw. Serum creatinine levels should be obtained prior to each bisphosphonate dose. Periodic 24-hour urine monitoring should be performed to assess for renal damage secondary to bisphosphonate use long term. Tailoring of Regimen: No specific data on the use of ixazomib in the elderly or other special populations has yet been reported. Lenalidomide should be dose-reduced in patients with renal impairment. Steroids such as dexamethasone should be administered in lower doses in the elderly to prevent steroid-associated psychosis. Primary and Secondary Efficacy Outcomes: Fifty patients were enrolled in phase II study reported at American Society of Hematology (ASH). 6 Overall responses (ORR) were observed in 59 of 64 (92%, 95% CI: 83-87) patients; when patients who went on to autologous stem-cell transplant were excluded, the ORR was 88% (37 patients): Responses of very good partial response (VGPR) were observed in 37 (58%; 95% CI: 45-70) patients, and complete response (CR) in 17 (27%; 95% CI: 16-39). The median duration of response for the entire cohort had not been reached, with responses reported durable for up to 2 years. The estimated 1-year PFS was 88% (95% CI: 74-95) and the 2-year PFS was 67% (95% CI: 27-85). The median overall survival (OS) had not been reached; estimated 1-year OS was 94% (95% CI: 84-98). 6 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
7 Patients 65 years treated in the phase II part of the study: o ORR: 88% (21 patients) [95% CI: 68-77] o CR or near-cr (ncr): 38% (9 patients) o VGPR: 33% (8 patients) o PR: 17% (4 patients) o 1-year PFS: 73% (95% CI: 49-87) o 1-year OS: 83% (95% CI: 62-93) Maintenance therapy with ixazomib in the phase I/II study of newly diagnosed, untreated multiple myeloma patients who received IRD: To date, the overall best confirmed/unconfirmed responses included: CR in 52% (11 patients), ncr in 62% (13 patients), and VGPR in 71% (15 patients), and 29% (6 patients) partial response (PR). The median time to first response ( PR) was 0.99 months (range ) and to best response was 7.46 months (range ). 33% of patients improved their response during maintenance, which included 2 VGPR to ncr, 3 VGPR to CR, 1 VGPR to stringent complete response (scr), and 1 CR to scr. At data cut-off, median duration of response was 26.5 mos (range ). Among 15 patients achieving VGPR, 5 (33%) had progressed; median duration of VGPR was 23.0 months (range ). 7 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
8 Strategies to Reduce Treatment-Associated Side Effects: Antidiarrheal agents (eg, loperamide) are recommended to mitigate diarrhea. Electrolyte monitoring (eg, potassium) to identify and correct electrolyte abnormalities should be performed. Patients should be pre-medicated with antiemetic drugs such as granisetron and ondansetron prior to each dose of ixazomib to prevent nausea and vomiting. Patients should be premedicated with corticosteroids (ie, dexamethasone) and antiemetics prior to each dose of ixazomib. A complete blood count with differential (CBC/diff) should be obtained to monitor neutropenia and thrombocytopenia and intervene (ie, dose reduction, discontinuation of the causative agent) if necessary. Standard aspirin or low-molecular-weight heparin (LMWH) prophylaxis is recommended for patients receiving lenalidomide-containing regimens. Corticosteroids such as dexamethasone can lead to many side effects such as hyperglycemia, mood swings, insomnia, and proximal muscle weakness. Prior to starting a corticosteroid-containing regimen, patients should be screened for a history of diabetes, mood disorders and psychiatric illnesses. Regular physical activity should be encouraged to combat muscle weakness and prevent VTEs. Monitoring Recommendations and Notes: Adverse events (as listed above under Safety ) should be monitored for and addressed at each visit. Regular CBC/diff and chemistry monitoring to assess for myelosuppression and hepatic/renal abnormalities is suggested. Periodic monitoring of blood glucose levels (to assess for hyperglycemia), mood disturbance, and sleep patterns related to corticosteroids is recommended. Patients should be educated regarding additional side effects of medications as listed above (primarily PN, gastrointestinal, signs/symptoms of VTE) and urged to report side effects to the treatment team. Adherence to therapy can be improved by intervening side effects in a timely manner. Objective monitoring of responses to the regimen should be performed on a monthly basis (by International Myeloma Working Group (IMWG) Uniform Response Criteria) and recorded. 8 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
9 References: 1. Ninlaro [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; Takeda. Newsroom. Press release. Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma. July 15, Accessed at on August 24, Takeda. Newsroom. Press release. January-March Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival. Release date: February 10, Accessed at on August 24, National Comprehensive Cancer Network [NCCN]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ). Multiple Myeloma. Version Kumar S, Berdeja JG, Niesvizky R, et al. Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide- Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. Blood [ASH Annual Meeting Abstracts]. 2014;124(21):Abstract Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13): Revlimid [prescribing information]. Summit, NJ: Celgene Corporation; Primary Author: Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN, Cleveland Clinic, Cleveland, Ohio External Reviewer: Katherine Sanvidge Shah, PharmD, BCOP Internal Reviewer: Eugene R. Tombler, PhD, Medical Director for MediCom Oncology and Managing Myeloma, Patrick Brooks, PharmD, Medical Director for MediCom Oncology and Managing Myeloma History: Version : Draft: 4/2015; External Review: 6/2015; Internal and Revisions: 7/2015 8/2015. Version : updated to reflect FDA approval for patients who have received at least one previous therapy, inclusion of NCCN recommended uses, NCCN preferred or other designation status, NCCN categories of evidence for recommendations 1/ Version IRD: Ixazomib/Lenalidomide/Dexamethasone 9 IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
CME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationNinlaro. (ixazomib) New Product Slideshow
Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationWARNINGS AND PRECAUTIONS
DOSING GUIDE INDICATION NINLARO (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE FOR UK MEDICAL AND TRADE MEDIA ONLY Takeda Presents Data from TOURMALINE-MM1 Study for Ixazomib, the First and Only Once-Weekly Oral Proteasome Inhibitor Studied in Phase III Clinical
More informationLong-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Renal Impairment DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Thrombocytopenia DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationMarc Geirnaert Director of Provincial Oncology Drug Program CancerCare Manitoba
Marc Geirnaert Director of Provincial Oncology Drug Program CancerCare Manitoba Advisory board participant for lenalidomide in 2013 Not applicable Understand the role of prophylaxis for herpes zoster Be
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationREVLIMID Dosing Guide
REVLIMID Dosing Guide Convenient Once-Daily Oral Dosing for MM, MCL, and MDS 1 REVLIMID (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMillennium Pharmaceuticals, Inc., Cambridge, MA; 11 Dana-Farber Cancer Institute, Boston, MA
Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma Shaji K. Kumar,
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationManaging Myeloma Regimen Protocols 1. Constituents of Regimen: Cyclophosphamide (Cy), bortezomib (Bor), dexamethasone (D)
Regimen Protocols CyBorD: Primary Therapy for Newly Diagnosed, Transplant Eligible/ Ineligible and Relapsed/Refractory MM Patients 1 Constituents of Regimen: Cyclophosphamide (Cy), bortezomib (Bor), dexamethasone
More informationMSN, ANP-BC, AOCNP1*, R.
R2V2: Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study Jonathan L. Kaufman, MD
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationREVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED APPROVAL BY FDA FOR TREATMENT OF MULTIPLE MYELOMA
Contact: Robert J. Hugin Brian P. Gill President and COO Senior Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID IN COMBINATION WITH DEXAMETHASONE snda GRANTED
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationREVLIMID is only available through a restricted distribution program, REVLIMID REMS. Please see additional Important Safety Information on pages
REVLIMID is only available through a restricted distribution program, REVLIMID REMS. Please see additional Important Safety Information on pages 11-12 and accompanying full Prescribing Information, including
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationPomalidomide and Dexamethasone Therapy
INDICATIONS FOR USE: Pomalidomide and Therapy Regimen Code INDICATION ICD10 Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationNCCP Chemotherapy Regimen. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
, Lenalidomide and Dexamethasone (KRd) Therapy - INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Reimbursement Status *, lenalidomide and dexamethasone therapy is indicated for the treatment of adult
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationBased on the preliminary results of the study, safety was consistent with the known safety profile of REVLIMID.
REVLIMID (LENALIDOMIDE) DEMONSTRATED A SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL (PFS) COMPARED WITH OBSERVATION IN A RANDOMIZED STUDY IN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA SUMMIT, N.J.
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationREVLIMID [lenalidomide] capsules, for oral use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide]
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Frontline Therapy for Newly Diagnosed Patients Saad Usmani, MD FACP Levine Cancer Institute Introduction: Case Presentation 64-year-old woman with
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Tomer Mark 1, Angelique Boyer 1, Adriana Rossi 1, Manan Shah 1, Roger Pearse 1, Faiza Zafar
More information* Dose may vary dependent on tolerability and co-morbidities
BC Cancer Protocol Summary for Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant Using Lenalidomide with Low-dose Dexamethasone Protocol Code Tumour Group Contact
More informationPomalidomide and Dexamethasone INDICATIONS FOR USE:
Pomalidomide and INDICATIONS FOR USE: INDICATION Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment
More informationBCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone
BCCA Protocol Summary for Therapy of Relapsed Multiple Myeloma Using Lenalidomide with Dexamethasone Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLDREL Lymphoma, Leukemia/BMT Dr.
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationPivotal phase 3 data show investigational R 2 signi cantly extended progression-free survival compared with rituximab plus placebo
NEWS RELEASE Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018 12/2/2018 Pivotal
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationM Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an
More informationExpert perspectives real-world clinical experiences in relapsed myeloma
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Expert perspectives real-world clinical experiences in relapsed myeloma This satellite
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationMedian duration of transfusion independence was 8.2 months
December 8, 2014 Results from Phase III Study of REVLIMID (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS),
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationStudy Rationale. Reference: Chanan-Khan, A., et al., ASH 2010, Abstract#1962. Reference: Whiteman, K., et al, AACR, 2009, Abstract#2799
Phase I Study of Lorvotuzumab Mertansine (LM) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM) Jesus Berdeja 1, Francisco
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationOF HIS TREATMENT FOR RELAPSED MULTIPLE MYELOMA. Understanding the steps on your treatment journey
EMMETT TAKES CHARGE OF HIS TREATMENT FOR RELAPSED MULTIPLE MYELOMA Understanding the steps on your treatment journey APPROVED USE KYPROLIS (carfilzomib) is a prescription medication used to treat patients
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.47 Subject: Revlimid Page: 1 of 6 Last Review Date: June 19, 2015 Revlimid Description Revlimid (lenalidomide)
More informationABSTRACTS 689, 901, 3668, and December 11, 2012
December 11, 2012 Data Evaluating Combination Treatments Including REVLIMID Plus Antibody Therapies in Patients with Various Difficult-to-Treat Forms of Non-Hodgkin Lymphoma Presented at the 54th American
More informationMayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More informationBC Cancer Protocol Summary for the Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality
BC Cancer Protocol Summary for the Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality Protocol Code Tumour Group Contact Physician MYBORMTN
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationCurrent treatment options for relapsed/refractory multiple myeloma in practice
Current treatment options for relapsed/refractory multiple myeloma in practice Professor Marίa-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain Please note that discussion throughout
More informationBortezomib, Thalidomide and Dexamethasone (VTD) 28 day
Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Indication First line treatment of multiple myeloma in patients who are eligible for stem cell transplantation. (NICE TA311) ICD-10 codes Codes with
More informationBC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide
BC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide Protocol Code Tumour Group Contact Physician Contact Pharmacist UMYLENMTN Lymphoma, Leukemia/BMT Dr. Kevin Song
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationREVLIMID [lenalidomide] capsules, for oral use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide]
More informationREVLIMID [lenalidomide] capsules, for oral use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REVLIMID safely and effectively. See full prescribing information for REVLIMID. REVLIMID [lenalidomide]
More informationIs sustained triplet therapy the new standard of care in relapsed/refractory multiple myeloma?
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Is sustained triplet therapy the new standard of care in relapsed/refractory multiple
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationDosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More information